Weekly Research Analysts’ Ratings Changes for Innoviva (INVA)

Several brokerages have updated their recommendations and price targets on shares of Innoviva (NASDAQ: INVA) in the last few weeks:

• 8/11/2026 – Innoviva was downgraded by Weiss Ratings from “buy (b)” to “hold (c+)”.
• 8/7/2026 – Innoviva had its price target lowered by Cantor Fitzgerald from $36.00 to $34.00. They now have an “overweight” rating on the stock.
• 8/1/2026 – Innoviva was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/31/2026 – Innoviva was downgraded by Zacks Research from “hold” to “strong sell”.
• 6/24/2026 – Innoviva had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 6/22/2026 – Innoviva had its “buy” rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.